25th Jan 2019 08:33
LONDON (Alliance News) - British drugmaker Indivior PLC said Friday that it has secured a temporary order to prevent US-based Alvogen Pine Brook LLC from launching its generic buprenorphine and naloxone sublingual film product in the US.
The US District Court for the District of New Jersey has granted Indivior a temporary restraining order that prevents Alvogen from launching its generic sublingual film product.
The order will will remain in place until February 7, when a preliminary injunction hearing will take place.
"We are pleased that the District of New Jersey has granted Indivior's motion for a TRO," said Indivior Chief Executive Shaun Thaxter.
"We will continue to vigorously pursue our infringement cases against Alvogen to protect our Suboxone Sublingual Film patent portfolio, including continuing to pursue the appeal of the US District Court for the District of Delaware's non-infringement decision related to US patents 8,603,514, as well as litigating our recently listed Orange Book patents for Suboxone Film," Thaxter added.
Suboxone sublingual film is an opioid addiction treatment that is dissolved in the mouth. Suboxone accounts for around 80% of Indivior's revenue.
In November 2018, a US court vacated an injunction against the Suboxone generic that was developed by Dr Reddy's Laboratories Ltd.
Dr Reddy intends to launch its generic on an "at-risk" basis as litigation and a patent infringement appeal surrounding the product are ongoing.
Shares in Indivior were trading flat on Friday morning at 114.35 pence each.
Related Shares:
Indivior